Recently, obinutuzumab was included in the Australian Pharmaceutical Benefits Scheme for use in first line, advanced or bulky stage 2, follicular lymphoma, providing more immunochemotherapy treatment options available than ever before. Rituximab with chemotherapy has been the standard of care since reimbursement in the late 1990s; however, obinutuzumab-based regimens have shown superior progression-free survival in comparison to rituximab-based options, albeit at an increased risk of grade ≥3 adverse events. As median overall survival approaches 20 years or more, the long-term effects and sequencing of any strategy should be considered. Here we discuss the considerations for selection of front-line therapy, based on evidence and local Australian clinician experience, in the management of first line follicular lymphoma.
INTRODUCTION
Now that there are more treatment combinations available for firstline follicular lymphoma, we are faced with a potential challenge to the long-standing standard of care. Is it just as simple as switching from rituximab to obinutuzumab? Can we base our decision purely on the efficacy and safety of the phase III study? The existing follicular lymphoma literature has several limitations that may impact on its real world application including the biases with selection into clinical trials, limited duration of follow-up and lack of patient reported outcome data.
Translation of clinical studies requires consideration of "real-world" factors including patient and disease characteristics such as age, comorbidities, disease stage, histological subtype and importantly, patient preference. We believe that clinicians should adopt a patientcentered approach that considers both efficacy and toxicity within each individual's context. In general, it is recommended to use the most efficacious and well-tolerated option first line so that the patient has the longest freedom from symptomatic disease and the burden of treatment, while minimizing risk of morbidity.
CURRENT OPTIONS FOR FIRST-LINE FOLLICULAR LYMPHOMA IN AUSTRALIA
The options for first-line treatment of follicular lymphoma, subsidized under the Australian Pharmaceutical Benefits Scheme (PBS), are rituximab or obinutuzumab with a chemotherapy backbone (bendamustine, CHOP [cyclophosphamide, hydroxydaunorubicin (doxorubicin), oncovin (vincristine), prednisone/prednisolone] or CVP [cyclophosphamide, vincristine, prednisolone]) plus the same antibody (rituximab or obinutuzumab) as maintenance therapy (excluding maintenance following rituximab-bendamustine therapy). 1 Rituximab chemotherapy has been the standard of care for follicular lymphoma based on its efficacy in combination with chemotherapy.
It has been studied in several large phase III trials in previously untreated follicular lymphoma, including the trial by Marcus et al. comparing rituximab-bendamustine with rituximab plus standard chemotherapy. 4 In addition, the value of rituximab maintenance following rituximab chemotherapy (CHOP or CVP) has been demonstrated in the PRIMA trial. This study showed that 2 years of rituximab maintenance therapy significantly improves PFS, albeit with increased infections. 5 PRIMA led to adoption of rituximab maintenance following R-CVP or R-CHOP induction. However, questions about the use of maintenance after bendamustine remained, because it has not been studied exclusively.
This means that evidence-based treatment decisions cannot always be made as there are data gaps in the design and sequence of consecutive studies, particularly with regard to chemotherapy and maintenance.
Obinutuzumab, like rituximab, is an anti-CD20 IgG1 monoclonal antibody. However, in contrast to rituximab, obinutuzumab is fully humanized, recognizes a unique epitope of CD20, and has a modified hinge region, resulting in spatial alterations to the CD20-mAb assembly complex on B cells. In addition the Fc region has been defucosylated enhancing Fc RIII receptor binding. 6, 7 The net effect of these changes is to augment antibody-dependent cellular cytotoxicity and phagocytosis, direct non-apoptotic cell death and diminish complementdependent cytotoxicity. 8 Treatment with obinutuzumab-and rituximab-based chemotherapy were compared in the phase III GALLIUM study in patients with previously untreated follicular lymphoma. 9 Treatment with obinutuzumab plus chemotherapy (CHOP, bendamustine or CVP), followed by obinutuzumab maintenance, significantly improved PFS and time to next anti-lymphoma treatment compared to rituximab plus chemotherapy followed by rituximab maintenance after a median follow up of 57.3 months. 10 The PFS rate was 78.1% for obinutuzumab-based chemotherapy ersus 67.2% for rituximab-based chemotherapy hazard ratio (HR 0.73; 95% CI, 0.59-0.90; P = 0.003). 10 No difference in OS was observed between the treatment arms; however, based on the 80% 10-year OS identified in the PRIMA study, several more years of follow up would be required for enough events to occur to detect a difference in survival in the GALLIUM study (i.e., with 10 years of follow up, there is an 80% chance of detecting a 6% improvement in OS at a significance of 0.05%). Furthermore, OS differences may not be observed with relapsing patients successfully salvaged with other therapies.
Patients who received obinutuzumab in the GALLIUM study were more likely than those who received rituximab to experience grade ≥3 adverse events (79.2% vs 71.2%) and serious adverse events (48.7% vs 42.2%), although the rate of adverse events resulting in death was the same (4.0%). 10 The most common adverse events in both arms included infusion-related reactions (IRRs), nausea and neutropenia.
This study led to obinutuzumab plus chemotherapy (with CHOP, bendamustine or CVP) and obinutuzumab maintenance (for all combinations) being subsidized by the Australian government in patients with CD20 + advanced follicular lymphoma.
Obinutuzumab dosing was based on pharmacokinetic studies and selected to achieve saturation of CD20 binding sites within the first treatment cycle. 11, 12 This is in contrast to rituximab, where no formal dose finding studies were performed. The 1000 mg dose of obinutuzumab was shown to rapidly saturate CD20 binding sites on the lymphoma cells, regardless of body surface area or body weight. 13 Furthermore, obinutuzumab has a very wide therapeutic index.
In follicular lymphoma, a dose of 1000 mg obinutuzumab is given on days 1, 8 and 15 of the first treatment cycle, and then on day 1 only for subsequent cycles of induction therapy (Table 1) . 14 In the GALLIUM study, obinutuzumab was administered for six 28-day cycles when combined with bendamustine and for eight 21-day cycles when combined with CHOP and CVP. 9 As patients received CHOP for six 21-day cycles only, patients receiving obinutuzumab-CHOP received obinutuzumab alone in cycles 7 and 8. Note that the dosing schedule for follicular lymphoma is different from that for chronic lymphocytic leukemia (CLL), where obinutuzumab-related infusion reactions are more common (Table 1) .
CONSIDERATIONS FOR CHOICE OF TREATMENT IN THE MANAGEMENT OF FIRST-LINE FOLLICULAR LYMPHOMA
There is no standard approach to the first-line treatment of follicular lymphoma. The choice of monoclonal antibody and chemotherapy backbone combination is based on a number of factors including patient age, comorbidities, disease stage, histological features, symptoms, toxicities, plans for maintenance therapy and patient preference.
It is important to appreciate that some older patients with advanced disease will have a near normal life expectancy, 15, 16 and therefore treatment that can result in long-term morbidity are best avoided. Of course, the availability of subsidized treatment also guides the treatment approach in Australia. We have highlighted in Table 2 a number of considerations when making the choice of induction therapies in advanced follicular lymphoma.
Choice of monoclonal antibody
As the pre-planned subanalysis of the Gallium study failed to identify a single patient population that would be more suitable for either monoclonal antibody, the choice of antibody should be based on efficacy and safety. 17 Important considerations when selecting a monoclonal antibody include judgment regarding the benefit of a prolonged treatmentfree interval (4 years' time to next treatment [TTNT] 84% vs 76.7%) versus the small increased risk of febrile neutropenia (7.4% vs 4.7%) and infusion reactions (12.3% vs 7.4%).
Choice of chemotherapy backbone
The choice of chemotherapy should be based on the patient's specific comorbidity profile and preference. Considerations include alopecia, neuropathy and cardiotoxicity with CHOP and increased nausea and rash, protracted lymphopenia and prolonged overall duration of treatment with bendamustine. It is worth noting that fatal adverse events were higher among patients receiving bendamustine in the GALLIUM trial regardless of whether the patient was randomized to rituximabor obinutuzumab-based chemotherapy (5% and 6% respectively vs 2% with CHOP or CVP). 18 Also, clinicians may choose not to treat grade If no IRR occurred during the previous infusion where the final infusion rate was ≥100 mg/h, infusions can be started at a rate of 100 mg/h and increased by 100 mg/h increments every 30 min to a maximum of 400 mg/h. If the patient experienced an IRR during the previous infusion administer at 50 mg/h. The rate of infusion can be escalated in increments of 50 mg/h every 30 mins to a maximum of 400 mg/h. Most data for R-B is in patients with Grade 1 or 2 FL; some clinicians avoid Bendamustinebendamustine in Grade 3A. Potential small increased risk of stem cell toxicity, second cancers and opportunistic infections in combination with maintenance. Increased mortality in those receiving bendamustine induction (post hoc analysis, GALLIUM study) Not recommended in patients with severe renal impairment AE, adverse event; B, bendamustine; FL, follicular lymphoma; FLIPI, Follicular Lymphoma International Prognostic Index; OS, overall survival; PFS, progression-free survival; MRD, minimal residual disease; POD24, progression of disease within 24 months; QoL, quality of life; R, rituximab; R-B, rituximabbendamustine; TTNT, time to next treatment.
IRR, infusion-related reaction

TA B L E 2 Considerations when selecting induction therapies in advanced follicular lymphoma
Monoclonal antibody Advantages Disadvantages
Rituximab
3A disease with bendamustine due to limited prospective data. The median OS in follicular lymphoma is now over 20 years, 19 therefore the late effects of chemotherapy (including therapy related myelodysplasia and acute myeloid leukaemia, acquired immune deficiency, infertility and stem cell toxicity) are very important considerations.
Considerations for later lines of therapy
Generally, a different chemotherapy backbone from that used in firstline therapy is used in the second line. Repeated cycles of purine analogues (including bendamustine) are generally not recommended, due to concerns about lymphodepletion, action and risk of myelodysplasia and other secondary neoplasms. 9, 18 For patients who receive primary therapy with bendamustine, R-CHOP may be preferred if the duration of the first remission was less than 3 years. R-CHOP may also be the preferred option if there was progression during or shortly after completion of maintenance and in the case of suspected histologic transformation to large B-cell lymphoma. Patients who are fit and are ≤70 years who progress within 2 years of induction (POD24, see Section 3.6) should be considered for salvage therapy and autologous stem cell transplant. 15 This higher risk population is also frequently included in clinical trials of novel agents, so such opportunities should be explored in every case.
Obinutuzumab-bendamustine is also PBS subsidized for 
Surrogate measures and their role in guiding the management of follicular lymphoma
As the median time to progression is now 10 years, and median OS is over 20 years, there is a need for surrogate endpoints to evaluate therapeutic strategies in follicular lymphoma in a reasonable timeframe.
Progression of disease by 24 months post induction (POD24), complete response at 30 months after initiation of treatment (CR30) and end of induction (EOI) positron emission tomography (PET) scanning have been suggested. However, only CR30 has been formally validated as a surrogate for PFS. [21] [22] [23] These surrogate endpoints, and others, provide us with additional information to assist in the decision-making process for treatment and management of follicular lymphoma.
Time to next treatment
The majority of patients with stage III/IV follicular lymphoma are still expected to relapse at some point and given that some of the novel/targeted agents require continuous dosing, treatment-free interval with good quality of life is a meaningful goal for patients. TTNT is considered more relevant to patients than PFS as low volume asymptomatic relapse does not require immediate treatment and patients can continue to live life normally. 24 A long TTNT enables patients to plan work, study, holidays, life events and finances. The TTNT in the GALLIUM study was 84.2 months in the obinutuzumab-chemotherapy arm and 76.7 months in the rituximab-chemotherapy arm (HR 0.70; 95% CI, 0.54-0.90; P = 0.0046). A similar TTNT of approximately 78 months with rituximab was also reported in recent update of the PRIMA study. 25 In clinical trials, frequent computerized tomography (CT) scans mean that progressive disease is detected earlier than in clinical practice. However, follow up is rarely performed beyond 5 years, therefore accurate determination of PFS is often not possible. In retrospective studies, where serial scans are not performed, TTNT is a more objective measure of progression. However, TTNT definition can vary, therefore a close reading of definitions in maintenance studies is required to understand the impact.
POD24
POD24 from initiation of chemotherapy has been identified as a marker of extremely poor outcome with only half of those progressing at this time being alive at 5 years. In the original POD24 study 20.8% of patients receiving R-CHOP had progressed within 2 years. 15 In the GALLIUM study, POD24 had been experienced by 18.9% (95% CI, 15.9%-22.4%) in the rituximab-chemotherapy arm, and 12.5% (95% CI, 10.1%-15.6%) in the obinutuzumab-chemotherapy arm, a relative risk reduction for early progression or death for any reason of 33.9% (95% CI, 12.8-49.8). 26 Patients who do not experience POD24 months may essentially have a normal life expectancy. 15, 16 
PET
PET is now the standard of care imaging modality for accurate staging and assessing disease characteristics at baseline. Although baseline PET may be used to select sites to biopsy to identify transformed disease in patients with a clinical suspicion of such, baseline maximum standardized uptake value did not predict future histological transformation from follicular lymphoma to aggressive lymphoma in 595 patients in the GALLIUM study. 27 Multiple studies have confirmed that a positive PET scan at EOI chemotherapy defines a group who fail to obtain complete metabolic response (CMR) with a five-fold risk of early progression and five-fold risk of death, and who may derive the greatest benefit from maintenance or consolidation therapies. 22, [28] [29] [30] [31] Radiotherapy may be considered where there are isolated sites that remain PET positive. EOI PET is useful in assisting patients to make life decisions based on the probability of relapse. IIIA. The study will quantitate the PFS benefit as well as the rate of infections from antibody maintenance in patients who achieve CMR, compared to those who do not receive maintenance. Patients who fail to achieve complete metabolic response will be randomized to antibody maintenance alone compared to maintenance with the addition of lenalidomide.
MRD
MRD is proposed as another surrogate measure of response, albeit limited by sensitivity. More sensitive MRD assays are currently under development and will likely be better predictors of clinical progression. In the GALLIUM study, 815/1101 (74%) patients with MRD evaluable samples had an MRD marker meeting the predefined quality criteria. Ninety-two percent of MRD evaluable patients receiving Gchemotherapy achieved MRD negativity vs 85% of those receiving Rchemotherapy. 32 Patients who achieved MRD negativity experienced longer PFS. Of 298 patients with both MRD and EOI PET analysis, 250 patients achieved both complete metabolic response (CMR) and MRD negativity. Risk of progression or death in patients achieving only CMR or MRD negativity was 2.1-fold greater than that in patients who achieved both, suggesting that EOI PET and MRD responses could provide complementary information. 33 Further data are required to understand the interaction between MRD status and EOI PET-CT results. PET-CT scans provide a more immediately applicable and measurable tool for prognostication at the EOI.
BEST PRACTICE GUIDANCE FOR MANAGING PATIENTS RECEIVING OBINUTUZUMAB IN FOLLICULAR LYMPHOMA
Obinutuzumab maintenance therapy
The benefit of rituximab maintenance (mainly following R-CHOP and R-CVP-based induction) was first demonstrated in the PRIMA study, 34 which lead to regulatory approval. However, reimbursement of rituximab maintenance following bendamustine-based induction was not approved in Australia based on a lack of safety and efficacy data in this setting.
In contrast, the GALLIUM study used maintenance in all arms and PBS subsidy is available for obinutuzumab maintenance following obinutuzumab-bendamustine therapy. However, it should be noted that there are no studies quantifying the additional benefit derived from maintenance therapy with obinutuzumab following obinutuzumab versus observation after first-line induction.
There are long-term safety and efficacy data supporting the use of rituximab from the follow up of the PRIMA, BRIGHT, FOLL05 and StiL NHL1 studies. The distinction between safety in induction and safety in maintenance is important, and there is an interaction between chemotherapy backbone and the safety of the antibody partner, in induction and likely also in maintenance. [34] [35] [36] [37] Consequently, tolerability of maintenance, choice of chemotherapy and the patient preference are key considerations when deciding whether maintenance therapy should be used. Some patients do not like the idea of returning to the hospital every 2-3 months for maintenance therapy, while other patients prioritize the prolonged period without second line chemotherapy.
Patients with a tendency to chest and sinus infections prior to induction are generally considered unsuitable for maintenance therapy, and such patients (13%) were excluded from enrollment in the MAIN-TAIN study of 2-year versus 4-year maintenance rituximab after Rbendamustine therapy. In GALLIUM, the incidence of adverse events, after Bendamustine chemotherapy, such as the risk of grade 3-5 infection, whether they received rituximab or obinutuzumab (induction and maintenance) was concerning (obinutuzumab-bendamustine 26%, Rbendamustine 20%, compared to obinutuzumab -CHOP and R-CHOP both 12% and obinutuzumab -CVP and R-CVP both 13%). 18 There were eight patients (2.4%) who received obinutuzumab -bendamustine who had fatal adverse events classified as "infections and infestations" compared with two patients (0.6%) in the R-bendamustine arm, one patient (0.5%) in the obinutuzumab -CHOP arm and no patients in the R-CHOP and obinutuzumab -CVP and R-CVP arms. 17 The MAINTAIN study 38 and post-hoc analysis of the BRIGHT study where patients were randomized to R-bendamustine or standard therapy did not raise the same concerns, but data collection for infectious complications was not prolonged in BRIGHT and these observations provide little information about the safety of maintenance. Also, prophylaxis against infection was not mandated in the GALLIUM and MAINTAIN studies and was used less often in the bendamustine arm. 9 Obinutuzumab-bendamustine followed by obinutuzumab maintenance is a reasonable option; however, the clinician should be aware of the increased number of fatal events observed in this arm in the GALLIUM study (mainly occurring during the maintenance phase) and consider prophylaxis and/or heightened awareness for opportunistic infections to facilitate early treatment withdrawal.
Does receiving first-line obinutuzumab impact on options at relapse?
The choice of second-line therapy will depend on factors such as whether progression of disease was within 24 months, whether the patient is a candidate for autologous stem cell transplant, whether histological transformation has occurred, which chemotherapy backbone was used in first line therapy, clinical trial availability and patient fitness. There are no data suggesting that patients who have progressive disease after obinutuzumab-chemotherapy will be any less responsive to second-line therapy than after rituximab-chemotherapy.
The survival of both the obinutuzumab and rituximab arms after a POD24 event was similar. 26 The approach to salvage therapy depends on the durability of 
IRRs: incidence, prevention and treatment, when using obinutuzumab
In the GALLIUM study, the incidence of IRRs higher with obinutuzumab (59.3%; 95% CI, 55.3%-63.2%) and rituximab (48.9%; 95% CI, 44.9%-52.9%, P < 0.001) with the majority of reactions occurring during induction. 9 Grade 3 or higher reactions occurred in 6.7% of patients receiving obinutuzumab and in 3.7% of those receiving rituximab. 17 Rates of Grade 3 or higher reactions were low during maintenance treatment. As in CLL, patients with follicular lymphoma with high tumor burden and/or high circulating white cell count may be at increased risk of severe IRRs.
IRRs occur mainly during the infusion of the first 1000 mg of obinutuzumab. At cycle 1, day 1 patients with very high tumor burden and/or high circulating white cell count may need to be admitted to hospital overnight. Dosing strategies to reduce IRRs are outlined in Table 1 . In contrast to patients with CLL, a split starting dose is usually not required in follicular lymphoma, but this may be considered in patients with a large circulating burden of lymphoma cells. Premedications with intravenous corticosteroid at least 60 min prior, as well as paracetamol and antihistamine can reduce the risk of IRRs. From the CLL11 study, 39 it was found that hydrocortisone was suboptimal, premedication should occur with either methylprednisolone 80 mg intravenously, or dexamethasone 20 mg intravenously. Hypotension may occur during obinutuzumab infusions, therefore consider withholding antihypertensive treatments for 12 hours prior to and throughout each infusion, and for the first hour after administration.
It is also important to prepare the patient for the possibility of an infusion reaction. Medical and nursing staff should be aware of the possibility of IRRs and there should be a plan in place for their management. Other recommendations are that the patient is well hydrated; has a second intravenous cannula inserted if at high risk of IRRs, and resuscitation facilities are close at hand.
The treatment strategy depends on the severity of the IRR. 14 Generally, the infusion should be stopped, steroids and antihistamines given and once symptoms have resolved the infusion recommenced at a slower rate. For patients with Grade 1 or 2 reactions, it may be sufficient to reduce the infusion rate, treat the symptoms and continue the infusion upon resolution of the symptoms. Patients with Grade 3 reactions require temporary interruption of the infusion and treatment of symptoms. Upon resolution of the symptoms, the infusion may be restarted at no more than half the rate used at the time the IRR occurred. If the patient does not experience any further IRR symptoms, the infusion rate may be escalated at increments and intervals as appropriate for the treatment dose. If a patient experiences a second occurrence of a Grade 3 IRR or a Grade 4 IRR, the infusion should be permanently discontinued.
Neutropenia: incidence, monitoring and treatment when using obinutuzumab
Neutropenia occurred more frequently with obinutuzumab than rituximab in the GALLIUM study (50.6% vs 45.1%, all grades; 43.9% vs 
Infections: incidence, considerations and prophylaxis when using obinutuzumab
In the GALLIUM study, there was a higher incidence of infection in the obinutuzumab arm than the rituximab arm (77.3% vs 70.0%), including higher rates of grade 3 or higher infection (19.8% vs 15.6%). 9, 17 There was no particular type of infection that was more common in the obinutuzumab arm. Patients should be screened for prior hepati- Data describing the rates of infection is scarce. Four cases of PJP were described in one Irish institution in patients following R-bendamustine treatment in patients who were elderly, heavily pretreated or who received doses of bendamustine in excess of the standard 90 mg/m 2 typically used. 19 A multicenter retrospective analysis of a cohort of patients in Israel treated with any bendamustine containing regimen over 5 years found that viral infections occurred in 11.3% of patients, of which 2.1% experienced HSV and 3.0% VZV infections. 40, 41 In addition, fluconazole can be prescribed in the small subset of patients, generally only older patients administered steroid containing regimens, who develop clinical thrush.
Tumor lysis syndrome: incidence, prevention and management when using obinutuzumab
The rates of tumor lysis syndrome (TLS) in the GALLIUM study were 1% and 0.5% (all grades) for obinutuzumab and rituximab, respectively. 9 In general, the risk of TLS is low in follicular lymphoma; however, patients with a high tumor burden and/or a high circulating lymphocyte count (>25 × 10 9 /L) and/or renal impairment (creatinine clearance <70 mL/min) are at higher risk of TLS and should be 
Thrombocytopenia and bleeding: incidence, prevention and management when using obinutuzumab
Grade 3-5 thrombocytopenia was reported in 6.1% of patients receiving obinutuzumab-chemotherapy in the GALLIUM study and no major bleeding signal was observed. 9 However, severe and life-threatening thrombocytopenia was noted in a small number of patients receiving obinutuzumab in the CLL11 study. Although there was no increase in fatal bleeding over rituximab, in CLL11, all 13 obinutuzumab-related events (four grade 4 and one serious) occurred in cycle 1.
To prevent serious bleeding, patients with moderate thrombocytopenia (platelet count less than 50 × 10 9 /L) or receiving anti-platelet therapy should have a specific bleeding management plan that may include cessation of anti-platelet agents prior to day 1 obinutuzumab.
These patients should be closely monitored for thrombocytopenia, especially during the first cycle; regular laboratory tests should be performed until the event resolves (weekly monitoring during cycle 1, and for later cycles pre-cycle blood test, and possibly a mid-cycle blood test depending on prior therapies), and dose delays should be considered in case of severe or life-threatening thrombocytopenia.
SUMMARY OF EXPERIENCE/PEER-PEER GUIDANCE
Despite many advances in the care of patients with follicular lymphoma, there are several gaps in our knowledge including the biological effect of specific genetic lesions, outcomes using obinutuzumabbendamustine without maintenance, geographical variation in infectious risk, long-term risk of hypogammaglobulinaemia, infections and secondary cancers, the role of MRD and PET scan in routine clinical care and the impact of various treatment strategies on quality of life. As follicular lymphoma is currently incurable, the majority of patients will require more than one line of therapy. Data on "whole of life" strategies derived from population-based registries may be useful to inform decisions regarding sequencing of therapies.
We understand that in Australia the approach to first-line therapies varies between institutions and individual clinicians and is very much centered around patient risks and priorities. Importantly, no contemporary trial in which patients were randomized to compare rituximabchemotherapy regimens (Stil-NHL1, BRIGHT, FOLL05) has demonstrated an OS benefit for one chemotherapy regimen over another.
Prior to the availability of obinutuzumab, established approaches to first-line treatment of follicular lymphoma included R-CHOP with rituximab maintenance in "fitter" patients, or R-bendamustine for six cycles with no maintenance or R-CVP plus rituximab maintenance if patients are less "fit."
With obinutuzumab available, the first-line treatment options now include obinutuzumab-CHOP and obinutuzumab maintenance if fit or obinutuzumab-bendamustine with maintenance in those, particularly younger patients, willing to trade off the increased risk of infections to avoid alopecia and peripheral neuropathy, and to optimize PFS. Obinutuzumab -CVP and obinutuzumab maintenance is a very reasonable option in the elderly and less fit. 
CONCLUSION
The efficacy of obinutuzumab in comparison to rituximab makes it a useful addition to the treatment choices for patients with previously untreated follicular lymphoma. In clinical trials, obinutuzumab has been associated with an improved PFS, albeit with a higher frequency of grade 3 and 4 adverse events, particularly IRRs, neutropenia and infections. However, our experience is that the majority of these events can be effectively managed, and it is uncommon that patients would need to withdraw from obinutuzumab treatment.
Although recent studies have demonstrated substantial improvement in progression-free survival and TTNT, they have failed to demonstrate a difference in OS. As the majority of patients have excellent outcomes with contemporary therapy, a very large study with extended follow up would be required to detect any difference in OS, if present.
Financial considerations may impact the ability of developing countries to deliver contemporary therapies such as obinutuzumab.
